Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
Go back to Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial| Quantum Technology Corp (NASDAQ: QNTM) | Delayed: 3.61 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.61 | 52 Week High | $2.00 | |||
| Open | $3.61 | 52 Week Low | $0.10 | |||
| Day High | $3.61 | P/E | N/A | |||
| Day Low | $3.61 | EPS | $0.00 | |||
| Volume | 67 | |||||
